Search Medical Condition
Please enter condition
Please choose location

Tianjin, China Clinical Trials

A listing of Tianjin, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (59) clinical trials

Compare Chemotherapy of XELOX for 4 Months to 6 Months After D2 Gastrectomy for Gastric Cancer Staged II or III.

Surgical resection is the cornerstone of treatment for patients with localised gastric cancer. Capecitabine plus oxaliplatin for 6 months after D2 gastrectomy is considered as effective postoperative adjuvant treatment for patients with operable stage II or III gastric cancer in CLASSIC trail. However, because of adverse events discontinuations in the ...

Phase

0.0 miles

Learn More »

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP) in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

The purpose of this study is to determine if the addition of daratumumab to VELCADE-melphalan-prednisone (VMP) will improve very good partial response (VGPR) or better compared with VMP alone.

Phase

0.0 miles

Learn More »

A Study to Compare Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

The primary purpose of this study is to compare the efficacy of daratumumab when combined with Velcade (bortezomib) and dexamethasone (DVd) to that of Velcade and dexamethasone (Vd), in terms of progression free survival (PFS) in Chinese participants with relapsed or refractory multiple myeloma (MM).

Phase

0.0 miles

Learn More »

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenstr m's Macroglobulinemia (WM)

Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 3 years), safety follow up (28 days); survival follow-up until data cutoff for final analysis.

Phase

0.0 miles

Learn More »

Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)

The purpose of this study is to evaluate the pharmacokinetics and safety of posaconazole intravenous solution in Chinese participants at high risk for invasive fungal infections. Neutropenic participants undergoing chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes will be enrolled in the study.

Phase

0.0 miles

Learn More »

The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC

BACKGROUND: Postoperative interferon-alpha (IFN-alpha) therapy improved survival in patients with hepatocellular carcinoma (HCC). MiR-26 is a predictive marker for the efficiency of postoperative interferon-alpha treatment in patients with HCC. Our study is to identify the Efficiency of Postoperative IFN-Alpha Treatment in low miR-26 expression Patients With HCC. METHODS: A quantitative ...

Phase N/A

0.0 miles

Learn More »

Objective Diagnostic Markers and Personalized Intervention in MDD Patients

Major depressive disorder (MDD) is one of the most common psychiatric disorders, with high recurrence rate, suicide rate and disability rate. It's reported that the global burden caused by MDD will be up to the second rank among all the disease burdens by 2020. China is also confronted with the ...

Phase N/A

0.0 miles

Learn More »

Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC

Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in advanced primary hepatocellular carcinoma.

Phase

0.0 miles

Learn More »

The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)

The purpose of the study is to test whether the health care provider access and training in CERTAIN (Checklist for Early Recognition and Treatment of Acute Illness), would facilitate timely and error free best-practice delivery and minimize preventable death and costly complications in critically ill patients.

Phase N/A

0.0 miles

Learn More »

A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

This web-based database was launched on June 30, 2012 and consists of tertiary or secondary hospitals with special interest and expertise on managing hepatitis B patients across mainland China. The main inclusion criteria for this registration are HBsAg-positivity 6 months, HBeAg positive or negative, with or without cirrhosis, either treatment-nave ...

Phase N/A

0.0 miles

Learn More »